SG11201809899RA - Method of treating hyperglycemia - Google Patents
Method of treating hyperglycemiaInfo
- Publication number
- SG11201809899RA SG11201809899RA SG11201809899RA SG11201809899RA SG11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA SG 11201809899R A SG11201809899R A SG 11201809899RA
- Authority
- SG
- Singapore
- Prior art keywords
- yuanqu
- vpm
- dist
- taiwan
- international
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111 0 1101 010 11111 010 11111 0 11 011 11111 11111 0101110111111101111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\") WO 2017/198177 Al 23 November 2017 (23.11.2017) WIPO I P C T (51) International Patent Classification: Taipei City, Taiwan 115 (CN). LEE, Meng-Ju; 7F., No.3-2, A61K 31/277 (2006.01) A61K 9/20 (2006.01) Yuanqu St., Nangang Dist., Taipei City, Taiwan 115 (CN). A61K 9/08 (2006.01) A61K 9/48 (2006.01) LIAO, Yi-Ping; 7F., No.3-2, Yuanqu St., Nangang Dist., A61K 9/14 (2006.01) A61P 3/10 (2006.01) Taipei City, Taiwan 115 (CN). YEH, Yu-Yin; 7F., No.3-2, (21) International Application Number: Yuanqu St., Nangang Dist., Taipei City, Taiwan 115 (CN). PCT/CN2017/084746 (74) Agent: CHINA ZHENGHE INTELLECTUAL PROP- (22) International Filing Date: ERTY AGENCY; Unit C7, Floor 17, Block 2, Xihuan 17 May 2017 (17.05.2017) Plaza No.1, Xizhimenwai Street, Xicheng District, Beijing 100044 (CN). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/339,131 20 May 2016 (20.05.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant: CENTER LABORATORIES, INC. HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, [CN/CN]; 7F., No.3-2, Yuanqu St., Nangang Dist., Taipei KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, City, Taiwan 115 (CN). MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (72) Inventors: HSU, Jui-Pao; 7F., No.3-2, Yuanqu St., Nan- SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — gang Dist., Taipei City, Taiwan 115 (CN). SHANE, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — Guang-Tzuu; 7F., No.3-2, Yuanqu St., Nangang Dist., = (54) Title: METHOD = _ FIG 3 = = _ = \"o —I ISM = CZ 800 - — E = ii) = t 600 - 0 = U) = = 400 - = ii) 0 200 - E 1=1 Vehicle, 1111111 Vehicle, OF .x. Metformin \ ‘,, ,, k' ' , \ K‘ \ s \ TREATING HYPERGLYCEMIA db/m+, 10mUkg ,;• . 24' . /, ': 2 .., ; •<' .'.-- ;' ,.?' ,:;,, , , 7 I '= — = — Imo 10mUkg - ZS CM =I + .i. N t 7 / : 7 R-VPM, R-VPM, R-VPM, .• so :\". — 15mg/kg, 30mg/kg, 50mg/kg, r---1 + bid bid bid P<0.05 \\'' s ks ks E3 MI =I ... R-VPM, R-VPM, R-VPM, ....._ * 15mg/kg, 30mg/kg, 50mg/kg, P<0.05 r—i + ' 'N bid bid bid ',` ,:• , ,,, ,, / + + + *** i l - 7 - — _ Metformin Metformin Metformin u- C) isCI IN Day ,-1 co C :N (57) : Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or 1-1 ----- disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, IN and disorders related thereto. In particular, the present invention relates to methods of using (R) - (+) -verapamil or a pharmaceutically © acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia. ei O [Continued on next page] WO 2017/198177 Al MIDEDIMOMOIDEIRMEMOMOHHHOEBERVOIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662339131P | 2016-05-20 | 2016-05-20 | |
PCT/CN2017/084746 WO2017198177A1 (en) | 2016-05-20 | 2017-05-17 | Method of treating hyperglycemia |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809899RA true SG11201809899RA (en) | 2018-12-28 |
Family
ID=60326464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809899RA SG11201809899RA (en) | 2016-05-20 | 2017-05-17 | Method of treating hyperglycemia |
Country Status (15)
Country | Link |
---|---|
US (2) | US9980935B2 (en) |
EP (1) | EP3413886A4 (en) |
JP (3) | JP6692903B2 (en) |
KR (3) | KR102200664B1 (en) |
CN (2) | CN108430467B (en) |
AU (1) | AU2017267006B2 (en) |
BR (1) | BR112018073688A2 (en) |
CA (2) | CA3003319C (en) |
HK (1) | HK1254471A1 (en) |
IL (1) | IL262994B2 (en) |
MX (1) | MX2018013943A (en) |
RU (2) | RU2020140694A (en) |
SG (1) | SG11201809899RA (en) |
TW (1) | TWI659738B (en) |
WO (1) | WO2017198177A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108430467B (en) * | 2016-05-20 | 2021-06-22 | 晟德大药厂股份有限公司 | Use of (R) - (+) -verapamil for the treatment of hyperglycemia and pharmaceutical compositions thereof |
US10639292B2 (en) | 2018-04-20 | 2020-05-05 | Center Laboratories, Inc. | Method of treating hyperglycemia |
EP3981401A1 (en) * | 2020-10-06 | 2022-04-13 | InSphero AG | Pharmaceutical combination for the treatment and/or prevention of diabetes comprising a calcium channel blocking agent and an incretin mimetic |
CN117241798A (en) * | 2021-04-29 | 2023-12-15 | 日东制药股份有限公司 | Pharmaceutical compositions comprising GPR40 promoters and SGLT-2 inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9616549D0 (en) * | 1996-08-06 | 1996-09-25 | Chiroscience Ltd | Therapeutic product and its use |
US20030092765A1 (en) * | 2001-11-15 | 2003-05-15 | John Kelly | Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil |
CN102210865A (en) * | 2005-06-03 | 2011-10-12 | 田边三菱制药株式会社 | Concomitant pharmaceutical agents and use thereof |
RU2338521C1 (en) * | 2007-02-28 | 2008-11-20 | Илья Николаевич Медведев | Method of fast depression of activity tromboplastin generation at patients with metabolic syndrome |
EP2405934B1 (en) * | 2009-03-12 | 2014-03-26 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
CN101869708A (en) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
WO2010138535A1 (en) * | 2009-05-27 | 2010-12-02 | Bristol-Myers Squibb Company | Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof |
TWI410630B (en) * | 2009-11-10 | 2013-10-01 | Ct Lab Inc | Method and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine dl receptor |
CA2780938A1 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
EP2573088A1 (en) * | 2011-09-26 | 2013-03-27 | Prous Institute for Biomedical Research, S.A. | Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof |
WO2015142865A2 (en) * | 2014-03-17 | 2015-09-24 | Massachusetts Institute Of Technology | Metakaryocidal treatments |
US9950995B2 (en) * | 2014-10-29 | 2018-04-24 | Center Laboratories, Inc. | Crystal forms of verapamil hydrochloride |
CN108430467B (en) * | 2016-05-20 | 2021-06-22 | 晟德大药厂股份有限公司 | Use of (R) - (+) -verapamil for the treatment of hyperglycemia and pharmaceutical compositions thereof |
-
2017
- 2017-05-17 CN CN201780003723.9A patent/CN108430467B/en active Active
- 2017-05-17 KR KR1020187012063A patent/KR102200664B1/en active IP Right Grant
- 2017-05-17 MX MX2018013943A patent/MX2018013943A/en unknown
- 2017-05-17 AU AU2017267006A patent/AU2017267006B2/en active Active
- 2017-05-17 CA CA3003319A patent/CA3003319C/en active Active
- 2017-05-17 CA CA3114057A patent/CA3114057A1/en not_active Abandoned
- 2017-05-17 CN CN202110545191.XA patent/CN113384571A/en active Pending
- 2017-05-17 RU RU2020140694A patent/RU2020140694A/en not_active Application Discontinuation
- 2017-05-17 SG SG11201809899RA patent/SG11201809899RA/en unknown
- 2017-05-17 EP EP17798740.1A patent/EP3413886A4/en not_active Withdrawn
- 2017-05-17 KR KR1020207037511A patent/KR20210000757A/en not_active Application Discontinuation
- 2017-05-17 JP JP2018521403A patent/JP6692903B2/en active Active
- 2017-05-17 WO PCT/CN2017/084746 patent/WO2017198177A1/en active Application Filing
- 2017-05-17 US US15/597,200 patent/US9980935B2/en active Active
- 2017-05-17 KR KR1020217031124A patent/KR102423967B1/en active IP Right Grant
- 2017-05-17 BR BR112018073688-0A patent/BR112018073688A2/en not_active IP Right Cessation
- 2017-05-17 TW TW106116239A patent/TWI659738B/en active
- 2017-05-17 RU RU2018139578A patent/RU2739255C2/en active
-
2018
- 2018-04-20 US US15/957,956 patent/US10278943B2/en active Active
- 2018-10-23 HK HK18113557.8A patent/HK1254471A1/en unknown
- 2018-11-13 IL IL262994A patent/IL262994B2/en unknown
-
2020
- 2020-02-27 JP JP2020032083A patent/JP2020100651A/en active Pending
-
2022
- 2022-01-11 JP JP2022002081A patent/JP7266327B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810872UA (en) | Composition and method for reducing neutropenia | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201809899RA (en) | Method of treating hyperglycemia | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase |